35 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 19 Phase 2, 10 Phase 3, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Phase 3 | 10 | Completed 9, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Dengue Hemorrhagic Fever: new trials by email Literature Review of Dengue Hemorrhagic Fever trials Research Report on Dengue Hemorrhagic Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gut Leakage' in Dengue Dengue, Dengue Hemorrhagic Fever | Recruiting | University of Oxford | 190 | 2026-08-01 | 2026-08-06 | |
| Evaluating Public Awareness and Preventive Actions for Dengue Fever in Sudan Amidst Ongoing Crises No intervention - Dengue Hemorrhagic Fever, Awareness | Completed | Research and Publication office | 164 | 2025-01-01 | 2025-10-03 | |
| The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Khyber Medical University Peshawar | 284 | 2024-12-17 | 2025-06-26 |
| Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients Fresh frozen plasma - Dengue Fever, Dengue Hemorrhagic Fever | Not applicable | Active not recruiting | Sheikh Hasina National Institute of Burn and Plastic Surgery | 300 | 2024-05-01 | 2024-10-15 |
| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults CYD Dengue Vaccine, Placebo (NaCl 0.9%) vaccine group - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 133 | 2019-11-06 | 2024-07-19 |
| Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Ivermectin - Dengue Hemorrhagic Fever | Phase 2 | Completed | Mahidol University | 24 | 2018-09-04 | 2021-02-24 |
| Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore Dengue Hemorrhagic Fever, Dengue Shock Syndrome | Completed | National University Hospital, Singapore | 200 | 2018-07-30 | 2019-09-13 | |
| Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects CYD Dengue Vaccine, Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed, Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 688 | 2016-12-19 | 2022-03-25 |
| Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine Dengue Fever, Dengue Hemorrhagic Fever | Completed | Sanofi Pasteur, a Sanofi Company | 30000 | 2016-12-14 | 2024-09-19 | |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant. - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 528 | 2016-12-01 | 2022-03-25 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® CYD Dengue Vaccine, Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 480 | 2016-11-16 | 2022-03-25 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule CYD Dengue Vaccine (5 dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 118 | 2016-07-01 | 2022-03-24 |
| Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age CYD Dengue Vaccine, Placebo (Sodium chloride 0.9%) - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1050 | 2016-05-02 | 2022-03-24 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule CYD Dengue Vaccine (5-dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 251 | 2016-04-14 | 2022-03-24 |
| Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine CYD Dengue Vaccine, Japanese Encephalitis Vaccine - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 90 | 2013-11-05 | 2022-03-24 |
| Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study Dengue, Dengue Fever | Completed | Sanofi Pasteur, a Sanofi Company | 3203 | 2013-09-10 | 2022-03-29 | |
| Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus, Placebo: NaCl 0.9% solution - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 189 | 2012-03-01 | 2022-04-05 |
| Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 390 | 2011-12-06 | 2022-03-24 |
| Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Live, attenuated dengue serotype 1, 2, 3, and 4 virus, Yellow fever vaccine, Measles, mumps, and rubella (MMR) vaccine - Dengue, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 792 | 2011-09-07 | 2022-03-25 |
| Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children Dengue, Dengue Fever | Completed | Sanofi Pasteur, a Sanofi Company | 667 | 2011-09-01 | 2018-01-11 |
Showing 20 of 38. Sign in to see all of them.
Severe Dengue (38) · Dengue (37) · Yellow Fever (2) · Acquired Immunodeficiency Syndrome (1) · Ascites (1) · Flavivirus Infections (1) · Hemorrhage (1) · Intestinal Diseases (1) · Thrombocytopenia (1) · Virus Diseases (1)
Arbovirus Infections (38) · Flaviviridae Infections (38) · Hemorrhagic Fevers, Viral (38) · Infections (38) · Mosquito-Borne Diseases (38) · RNA Virus Infections (38) · Vector Borne Diseases (38) · Flavivirus Infections (37) · Virus Diseases (37) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood Platelet Disorders (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Cytopenia (1)
Sodium Chloride (7) · Dengue Vaccines (5) · Measles-Mumps-Rubella Vaccine (3) · adacel (3) · ChimeriVax (2) · Dosage Forms (2) · Pneumococcal Vaccines (2) · Solutions (2) · Tetanus Toxoid (2) · Yellow Fever Vaccine (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Haemophilus Vaccines (1) · Hepatitis A Vaccines (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)
Sanofi Pasteur, a Sanofi Company (25) · Sanofi (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Khyber Medical University Peshawar (1) · Mahidol University (1) · National University Hospital, Singapore (1) · Research and Publication office (1) · Sheikh Hasina National Institute of Burn and Plastic Surgery (1) · U.S. Army Medical Research and Development Command (1) · University of Oxford (1)
Mexico (6) · Colombia (5) · United States (5) · Brazil (4) · Philippines (4) · Puerto Rico (4) · Thailand (4) · Honduras (3) · Malaysia (3) · Singapore (3) · Australia (2) · Bangladesh (2) · India (2) · Peru (2) · Vietnam (2)
Anna Durbin, MD (2) · Akhtar Sherin, MBBS,MHR,PHD (1) · Alberto Santiago-Cornier, MD (1) · Anna Quintero, MD (1) · Ashraful Hoque, DBST (1) · Beth Kirkpatrick, MD (1) · Clemente Diaz-Perez, MD (1) · Domingo Chardon-Feliciano, MD (1) · Evelyn Matta-Fontanet, MD (1) · Ines O. Esquilin-Rivera, MD (1) · Javier Morales-Ramirez, MD (1) · Jorge Bertran-Pasarell, MD (1)
PMID 26214039, PMID 29897841, PMID 33822015, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28871961, PMID 29300876, PMID 32932330, PMID 33212068, PMID 34003796, PMID 34219653, PMID 35659904, PMID 15272410, PMID 15577938, PMID 16603571, PMID 19292665, PMID 19822889, PMID 21208923, PMID 21976579, PMID 22863660, PMID 22894958, PMID 22975340, PMID 23540847, PMID 23563266, PMID 23839107, PMID 24021313, PMID 24067553, PMID 24135573, PMID 24189367, PMID 25018116, PMID 25230594, PMID 25365753, PMID 25483647, PMID 26175027, PMID 26279339, PMID 26291554, PMID 26614588, PMID 26639777, PMID 27102820, PMID 27414655, PMID 27532617, PMID 27601343, PMID 27825949, PMID 28590795, PMID 28598256, PMID 28968794, PMID 29408333, PMID 30241510, PMID 30986790
2014 (6), 2019 (3)